Navigation Links
Mylan Launches First Generic Version of Antihypertensive Sular(R) ER in the United States
Date:7/28/2008

PITTSBURGH, July 28 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE: MYL) today announced that its subsidiary, Mylan Pharmaceuticals Inc., has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Nisoldipine Extended-release (ER) Tablets, 20 mg, 30 mg and 40 mg.

Nisoldipine ER Tablets, indicated for the treatment of hypertension, are the generic version of Sciele Pharma's Sular(R) ER Tablets, which had annual U.S. sales of approximately $94 million for the 12 months ending March 31, 2008, for these three strengths. Mylan's Nisoldipine ER, which is being shipped immediately, is the first generic version of Sular ER to be introduced in the United States.

Currently, Mylan has 93 ANDAs pending FDA approval, 21 of which are potential first-to-file opportunities.

Mylan Inc., with a presence in more than 90 countries, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest - and highest quality - product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's second largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies.


'/>"/>
SOURCE Mylan Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Mylan Announces Pricing of Tender Offers for its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015
2. Mylan to Host Investor Day on October 3, 2007
3. Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD
4. Mylan Announces Appointment of Steven G. Zylstra as Vice President of Global Corporate Communication and Public Relations
5. Mylan Announces Tentative FDA Approval for Lamotrigine Tablets
6. Mylan Announces Final FDA Approval for Balsalazide Disodium Capsules
7. Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement
8. Mylan Announces Final FDA Approval for Ropinirole Hydrochloride Tablets
9. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
10. Novozymes Launches Enzyme to Reduce Acrylamide in Food
11. Enova Medical Launches Exos Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... Pismo Beach, CA (PRWEB) June 03, 2015 ... passed a Senate Energy, Utilities and Communications Committee (11-0) and ... the DA CAP) and renewable energy. , The Committee Chairman ... amended to increase the CAP by 8,000 GWh and would ... the utility wait list. , This “Wait List” and ...
(Date:6/3/2015)... Milan, Tennessee (PRWEB) June 03, 2015 ... facility in Milan, Tennessee to support the RCBC Waste ... Energy is fourth generation in the family business, ... since 1908. His family added recycling to their ... waste and recycling services to the Fortune 500 companies ...
(Date:6/3/2015)... June 03, 2015 Marktech Optoelectronics is ... Photodiodes. Marktech APD’s have an internal gain mechanism, fast ... the near infrared region. These APD’s are recommended for ... is needed to overcome high pre-amp noise. In addition, ... and are ideal for extreme low-level light detection and ...
(Date:6/2/2015)... TapImmune, Inc. (OTCQB: TPIV), a clinical stage cancer immunotherapy ... whereby the institutional investors will have the option to ... up to $4.93M in near term funding, pending closing ... restructured terms and subject to certain market conditions, the ... in a larger influx of capital to fund the ...
Breaking Biology Technology:Bmark Energy Announces the Sign-up Deadline for Companies Interested in California’s Direct Access Program is June 12th, 2015 at 5:00pm. 2Marktech Introduces New Line of APDs 2TapImmune Announces Agreement To Facilitate Near Term Capital Infusion; Expediting Path Toward Phase II Trial Initiation 2TapImmune Announces Agreement To Facilitate Near Term Capital Infusion; Expediting Path Toward Phase II Trial Initiation 3
... KANSAS CITY, Kansas , Aug. 5 Oncimmune® ... test that aids physicians in risk assessment and the early ... study that demonstrates the clinical validity of the test. The study ... Diagnosis " is now available on line at Annals of ...
... how a new type of experimental antibiotic can ... treatments [1]. The findings could ultimately help scientists ... responsible for many hospital and community-acquired infections. ... team of researchers from GlaxoSmithKline (GSK) captured a ...
... , Aug. 4 Forte, LLC, ... a web-based probate database and estate recovery application ... Probate Finder OnDemand provides access to a proprietary ... records, powerful matching algorithms that accurately match deceased ...
Cached Biology Technology:New Study Demonstrates Clinical Validity of EarlyCDT-Lung™ 2New Study Demonstrates Clinical Validity of EarlyCDT-Lung™ 3New Study Demonstrates Clinical Validity of EarlyCDT-Lung™ 4New Study Demonstrates Clinical Validity of EarlyCDT-Lung™ 5New Study Demonstrates Clinical Validity of EarlyCDT-Lung™ 6Image of new antibiotic in action opens up new opportunities to combat antibacterial resistance 2Forte Launches Probate Finder OnDemand™ 2Forte Launches Probate Finder OnDemand™ 3
(Date:4/20/2015)... PASADENA, Calif. , April 20, 2015 ... San Gabriel Valley to implant a new miniaturized, wireless ... HF System is the first and only FDA-approved heart ... reduce hospital admissions when used by physicians to manage ... a sensor that is implanted in the pulmonary artery ...
(Date:4/17/2015)... Increasing adoption in ... to drive biometric systems market in ... According to a recently released TechSci Research ... biometric systems market in Saudi Arabia ... CAGR of over 22% through 2020. The market ...
(Date:4/14/2015)... April 14, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces ... the 2015 New York Design Awards under the category  ... York City Design Awards are part of a global ... 2,500 ratings from the marketplace, industry and judging panel. ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3
... new, more effective and personalized cancer treatments, Horizon Discovery, ... Reserve University exclusive rights to a panel of new ... Zhenghe John Wang, assistant professor of genetics at the ... initially for 10 years and includes up-front fees and ...
... Institute at Virginia Tech have discovered how abscisic ... properties for the treatment of disease, helps fight ... published in the November 2010 Journal of ... for the development of treatments for inflammatory and ...
... Mich. The risk of esophageal cancer among patients ... as high as many may think, according to new ... considered a relative risk for developing esophageal adenocarcinoma, but ... M.D., M.Sc., an investigator with the Department of Veterans ...
Cached Biology News:Isogenic cell models for cancer research exclusively licensed to Horizon Discovery 2Researchers discover how natural drug fights inflammation 2Researchers discover how natural drug fights inflammation 3Esophageal cancer risk lower than expected for patients with GERD 2
A component of the Acridinium protein labeling kit....
... to human XAB2 (amino terminus) XAB2 ... its interaction with XPA. Immunoprecipitation experiments have ... interacts with the transcription-coupled repair-specific proteins CSA ... polymerase II. Microinjection experiments with XAB2 antibodies ...
...
... calibration, and validation (MCV) plate ... plate used for hands-free startup, ... using the Bio-Plex suspension array ... for use with Bio-Plex Manager ...
Biology Products: